|
Dementia patients sought for sleep drug trial
The first study of its kind looking at the effects of the sleep hormone on dementia is being launched by a Glasgow company.
Conducted by CPS Research, the trial is looking for 100 Scottish patients to help investigate the use of melatonin as an add-on treatment in the illness, which often involves sleeping difficulties.
Research suggests dementia patients produce very little melatonin, the natural hormone produced to prepare the body for sleep and to maintain it. CPS Research is looking for 100 patients throughout Scotland to take part in a nine-month study which will mark the start of a worldwide trial.
It will test the effects of new drug Circadin, produced by Neurim Pharmaceuticals, which has already been shown to alleviate the symptoms of sleeplessness and anxiety in dementia patients
. Mondy 5 July 2010
Circadin is approved in the EU for treatment
of Primary Insomnia in patients aged 55 or over for up to 3 months.
Tel Aviv, July 5, 2010. Neurim Pharmaceuticals (www.Neurim.com) confirmed today that the
European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months).
Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over.
11 June 2009
| 
